Ferrets as experimental animals {#s0005}
===============================

Domestic ferrets (*Mustela putorius furo*) are small carnivores belonging to the *Mustelidae* family. Their closest wild relatives are wild European ferrets (*M. putorius*), European polecats (*M. furo*) and the steppe polecat (*M. eversmannii*), and interbreeding among these species produces fertile offspring, illustrating the close relationship ([@bib98]). Due to their relatively small size and their similarity to humans with respect to aspects of their anatomy, physiology, and metabolism, they are increasingly considered an alternative to larger animal models such as dogs and non-human primates ([@bib33]). Ferrets are available from different commercial breeders, some of which are even offering specific pathogen free (SPF) animals. Seronegative animals, while of particular interest for the infectious disease community, are difficult to maintain due to the natural susceptibility of ferrets for human respiratory viruses. Breeders offer pre-testing of animals prior to purchase and use HEPA-filtered transport cages to minimize risk of exposure during shipping, but the serostatus of all animals has to be verified after arrival. In addition, personal protective equipment such as N95 masks or powered air purifying respirators (PAPRs) should be worn for all interactions with the animals to prevent accidental exposure by infected staff.

The animals are social and should be housed in same sex groups whenever possible ( [Fig. 1](#f0005){ref-type="fig"}A and B). Many of the standard rabbit caging systems can be used to house ferrets during experiments ([Fig. 1](#f0005){ref-type="fig"}C and D). The spacing of the grid walls and food receptacles may have to be adapted to prevent escape, and hiding places such as tubing or tunnel, hammocks, or nesting boxes have to be provided ([@bib2]). Because of their value for pathogenesis studies with viruses requiring high containment, different individually ventilated cage (IVC) systems have been also been developed. An adult female ferret weighs 700--1000 g, while males weigh 1400--2000 g, thus allowing repeat blood sampling at volumes sufficient for immunological analyses over the course of an infection ([@bib9]). While small blood samples can be obtained from the tail or leg veins, larger volumes required for the isolation of peripheral blood mononuclear cells are best collected from the anterior vena cava ( [Fig. 2](#f0010){ref-type="fig"}A and B) or the internal jugular vein ([Fig. 2](#f0010){ref-type="fig"}C). The sexual weight dimorphism together with the requirement for inducing ovulation in female ferrets in estrus has led many researchers to preferentially use males ([@bib52], [@bib169]).Fig. 1Examples of different cage types for ferret housing. Longterm free-range housing in same sex groups. Environmental enrichment like hammocks, tubes, and additional levels for climbing are provided (A, B). During ongoing experiments the animals are housed in pairs in different cage types connected by tubes or openings in separating walls (C, D).Fig. 2Large volume blood collection sites. The anterior vena cava (A, B) and the internal jugular vein (C) allow collection of larger blood volumes.

Following the fortuitous discovery of the natural susceptibility of ferrets to human influenza viruses in the 1930s ([@bib173]), they were found to reproduce the human course of disease of a number of human respiratory viruses including respiratory syncytial virus (RSV), parainfluenzaviruses (PIV), and severe acute respiratory syndrome (SARS)-coronavirus ( [Fig. 3](#f0015){ref-type="fig"}). In addition to the presence of the respective receptors, the fact that anatomic proportions of the ferret upper and lower respiratory tracts, the density of submucosal glands in the bronchial wall and the number of generations of terminal bronchioles are all reproduce the situation in the human respiratory tract likely contributes to this effect ([@bib80], [@bib157]). With technical developments enabling infection via the ocular route or by aerosol, the impact of the inoculation route and volume on pathogenesis have been increasingly recognized ([@bib3], [@bib5], [@bib11], [@bib89], [@bib124]). For most studies however, the animals are inoculated intranasally with volumes ranging from 0.1 to 1 ml.Fig. 3Viruses investigated in ferrets. Viruses from different families discussed in this review that have been studied in ferrets.

Influenza virus {#s0010}
===============

In the context of infectious disease research, ferrets are most widely known as model for the study of influenza viruses, which belong to the *Orthomyxoviridae* family ([@bib136]). Influenza A, and to a lesser extent influenza B, viruses cause annual epidemics with an estimated 250,000--500,000 deaths worldwide. While humans are the only natural reservoir for influenza B, influenza A infects a broad range of avian and mammalian species with aquatic birds acting as principal reservoir. Among livestock, infections in poultry and pigs have the greatest economic impact, but horses, and more recently dogs, can also be affected. Avian and swine influenza A viruses are of particular public health relevance because their close contact with humans provides multiple opportunities for interspecies adaptation and transmission ([@bib136]).

Influenza A viruses are grouped into different subtypes according to the antigenicity of their surface glycoproteins, which are the principal targets of the neutralizing antibody response ([@bib57], [@bib136]). So far, 18 hemagglutinin (HA, H1--H18) and 11 neuraminidase (NA, N1--N11) subtypes have been identified ([@bib191], [@bib192]). Introduction of a new influenza A subtype into the human population can result in a pandemic with increased morbidity and mortality ([@bib7], [@bib81]). Avian influenza viruses are further classified in low pathogenic (LPAIV) and highly pathogenic avian influenza viruses (HPAIV), according to their HA cleavage site: LPAIV HAs carry a monobasic cleavage site, which can only be activated by proteases present in the avian respiratory tract, while HPAIV HAs are activated by subtilisin-like proteases present in every cell due to their polybasic cleavage site ([@bib8]).

Ferrets became the animal model of choice for influenza research when the first isolation of an influenza virus succeeded in this species ([@bib173]), and they have made remarkable contributions to our understanding of influenza biology ever since. In addition to being naturally susceptible to human influenza A strains, the clinical course of disease in ferrets reproduces key aspects of human disease including fever, lethargy and signs of upper and sometimes lower respiratory infection ([@bib18], [@bib172]). The similar influenza receptor distribution in the human and ferret respiratory system likely represents an important contributing factor: in the upper respiratory tract of both species, there is a high density of alpha 2,6-linked sialic acids (SAα2,6), while SAα2,6 as well as alpha 2,3-linked sialic acids (SAα2,3) are present in the lower respiratory tract ([@bib170], [@bib201]). As seen in adult human patients with uncomplicated influenza, infection of ferrets with seasonal H1N1 and H3N2 strains, which preferentially bind to SAα2,6, results in a mild to moderate disease characterized by extensive infection of the upper respiratory tract with limited spread to the lung ([@bib75], [@bib197]). In contrast, highly pathogenic influenza viruses, which have a higher affinity to SAα2,3, are always associated with severe pneumonia and widespread infection throughout the lung ([@bib7], [@bib93], [@bib130], [@bib170], [@bib201]), and in the case of certain strains also lead to neurologic and gastrointestinal involvement ([@bib56]). The assessment of the reconstructed pandemic H1N1 1918 virus in ferrets not only demonstrated the high virulence of this historic virus compared to a seasonal human H1N1 strain ([@bib188], [@bib194]), but also revealed that two amino acid changes in the HA protein were sufficient to switch the receptor specificity from SAα2,6 to SAα2,3 and abolish respiratory droplet transmission ([@bib195]), illustrating the important role of receptor specificity in influenza pathogenesis.

The similarity in influenza susceptibility between humans and ferrets is increasingly exploited to gain insights into the transmissibility and virulence of new isolates. Human-adapted seasonal influenza viruses spread through direct or indirect contact or respiratory droplets ([@bib20]), while infections with avian viruses are usually associated with close contact to infected poultry and are rarely transmitted. Transmissibility assessments of different HPAIs in ferrets have confirmed the poor transmissibility observed in the field ([@bib113]). However, there is great concern that one of these viruses acquires the capacity for aerosol spread and causes a pandemic ([@bib119], [@bib174]). Characterization of transmission determinants using genetically modified H5N1 viruses revealed that only five amino acid changes in the HA, PB1, and PB2 proteins were sufficient to enable efficient respiratory droplet transmission between ferrets ([@bib70], [@bib78], [@bib104]). Most of these mutations had already been described to play an important role in influenza virulence in ferrets and mice by either affecting replication efficiency or altering virus tropism ([@bib29], [@bib68], [@bib112], [@bib171]). In contrast to HPAI H5N1, the recently emerged human H7N9 isolates display a natural affinity for both SAα2,6 and SAα2,3 receptors. Even though they replicate efficiently in the upper and lower respiratory tract of humans and ferrets, transmission studies have so far yielded contradictory results ranging from reports of efficient airborne transmission over reduced aerosol transmission compared to seasonal and pandemic H1N1 strains to contact transmission only ([@bib6], [@bib155]).

The value of the ferret model to rapidly gauge the virulence of a newly emerging virus first became apparent during the H1N1 2009 pandemic. Evaluation of early isolates indicated an increased morbidity and higher pathogenicity compared to seasonal H1N1 strains but similar transmission efficiency ([@bib114], [@bib126]), thereby providing valuable information to public health officials. A large body of work investigating the pathogenesis and transmissibility of HPAI H5N1, H7N1, and H9N1 strains isolated from human cases or poultry provides a framework for the pandemic risk assessment of new viruses emerging from the animal reservoir ([@bib86], [@bib105], [@bib113], [@bib179], [@bib213]). Recently, avian H3N8 influenza viruses isolated from seals were found to have naturally acquired mutations known to increase transmissibility, demonstrated increased affinity for mammalian SAα2,6 receptors, and were transmitted via respiratory droplets between ferrets ([@bib84]), suggesting a pandemic potential for these viruses. This year, a novel highly pathogenic H5N8 virus was isolated from outbreaks in poultry first in Korea and China, and more recently also in Europe and Canada ([@bib49], [@bib92], [@bib209]). The virus causes moderate to severe disease in ferrets, but so far no avian-to-human transmission has been observed ([@bib85]). This continued emergence of new influenza strains in birds and mammals not only requires active surveillance but also the need for systematic characterization of their pandemic potential including pathogenesis studies in ferrets.

Despite the limited availability of ferret-specific immunological reagents, investigation of innate host responses based on mRNA expression levels, either by quantitative real-time RT-PCR or using a canine microarray, revealed profiles similar to those seen in patients, thereby illustrating the value of this animal model not only for virulence assessment but also the characterization of host responses ([@bib27], [@bib83], [@bib111], [@bib121]). While seasonal influenza strains are generally associated with a rapid rise and fall of type I and II interferons and TNFα during the first days after infection ([@bib163], [@bib181]), highly pathogenic H5N1 strains lead to a more sustained expression of interferon response genes and higher expression levels of cytokines and inflammatory mediators in the lungs ([@bib27]). Since such a hypercytokinemia or cytokine storm is also observed in H5N1 patients ([@bib40], [@bib141], [@bib190]) a more detailed characterization of the underlying pathomechanism in ferrets, using newly developed tools and assays and including more detailed kinetics of lymphocyte subsets, hematological parameters and serum chemistry profiles ([@bib4]), may yield innovative therapeutic approaches.

The ferret model also remains the gold standard for efficacy assessments of new vaccine strategies and therapeutic approaches. These studies are usually performed using seronegative animals to eliminate additional confounding factors, even though this does not reflect the epidemiological situation in the human population, where most adults have been exposed to at least one, but likely several, strains of the circulating subtypes ([@bib10], [@bib51], [@bib72]). At this time, inactivated influenza vaccines and live-attenuated influenza vaccines (LAIV) are licensed in most countries ([@bib95]). While LAIV induce a stronger immune response in naïve individuals, inactivated vaccines are more immunogenic in the presence of pre-existing immunity. In the context of the annual vaccination campaigns, LAIV are thus primarily given to children and young adults ([@bib158]). The potential of LAIV to induce a broader and more efficient immune response against newly emerging strains has been investigated extensively. Studies in ferrets demonstrated that a recombinant H5N1 LAIV elicited a broad cross-protection against different H5N1 sublineages ([@bib99], [@bib177]). More recently, it was shown that immunization with LAIV H7N3 and H7N7 resulted in cross protection against the newly emerged H7N9 virus ([@bib211]).

The immunogenicity and extent of cross-protection have also been investigated for inactivated pandemic vaccines. In general, whole-virus inactivated vaccines induce robust responses after a single dose and may even protect against antigenetically mismatched viruses ([@bib59], [@bib149], [@bib175]). In contrast, split-virus or subunit vaccines are less immunogenic, and more than one dose or the addition of an adjuvant are required to protect naïve individuals ([@bib21], [@bib39], [@bib43], [@bib102]). The development of safe and efficacious adjuvants is of great relevance in the context of pandemic preparedness, since the use of adjuvants reduces the amount of antigen needed per dose ([@bib32], [@bib135]). In addition, the development of adjuvanted seasonal vaccines is considered for seniors, who often respond poorly to the currently used non-adjuvanted inactivated vaccines ([@bib1], [@bib196]).

A comprehensive overview of innovative vaccine approaches against influenza is beyond the scope of this review. Among the most promising candidates are virus-like particles (VLPs) composed of the M1 matrix protein together with the HA and NA proteins. Intranasal or intramuscular vaccination with such VLPs containing H5, H7 and H9 proteins, or the H1 protein alone, induced an immune response against all HAs present and protected ferrets from challenge with multiple avian influenza viruses ([@bib110], [@bib151], [@bib160], [@bib193]). Different viral vector-based approaches have also been developed to the clinical trial stage. Among those, recombinant modified vaccinia virus Ankara (MVA) expressing different HA subtypes have demonstrated efficacy in ferrets and recent in first-in-man clinical trials have confirmed the immunogenicity in humans ([@bib88], [@bib90], [@bib156]). DNA- and more recently RNA-based vaccine candidates have great appeal in a pandemic context, since they can be produced rapidly and at large scale. DNA vaccines expressing single or multiple HA proteins alone or in combination with NA induce protective T and B cell responses in different animal models, especially in the context of prime-boost regimen with other vaccine candidates ([@bib19], [@bib103], [@bib146], [@bib154], [@bib176]). In a first proof-of-concept study, a PR8-HA-expressing RNA vaccine induced an immune response similar to approved influenza vaccines in ferrets and pigs ([@bib145]), indicating the feasibility of this approach. However, despite recent progress using *in vivo* electroporation or gene guns ([@bib94], [@bib212]), efficient DNA or RNA delivery remains a major obstacle for the implementation of this technology.

At this time, there are two classes of commercially available drugs against influenza, adamantane-derivatives, which inhibit the M2 ion channel, and neuraminidase inhibitors. In addition, the viral polymerase inhibitor favipiravir has received regulatory approval in Japan for use against influenza in 2014 ([@bib54], [@bib127]). Early on, ferret studies demonstrated the rapid emergence of antiviral resistance against adamantanes and the transmission of drug-resistant strains without loss of virulence ([@bib71], [@bib183]), thereby predicting todays resistance of all circulating seasonal influenza strains ([@bib22], [@bib23]). Nonetheless, adamantanes may still be useful in the context of a pandemic strain carrying a non-resistant M segment of animal origin ([@bib129]). Ferret studies also demonstrated the efficacy of neuraminidase inhibitors against lethal infection with different H5N1 strains ([@bib12], [@bib13], [@bib58]), which are now an integral part of pandemic preparedness strategies. After the emergence of oseltamivir-resistant strains, studies in ferrets have been used to characterize the impact of the mutations involved and to investigate the fitness cost associated with this resistance ([@bib205]). Ferret studies thus remain an integral part in the development of new prophylactic and therapeutic strategies against influenza.

Paramyxoviruses {#s0015}
===============

Henipaviruses {#s0020}
-------------

Hendra (HeV) and Nipah (NiV) viruses belong to the genus Henipavirus within the *Paramyxoviridae* family. Their natural hosts are fruit bats of the family *Pteropodidae* that can be found in South-East Asia, Australia and Africa ([@bib69], [@bib134], [@bib214]). Infected bats shed the virus in urine, thereby infecting other species. Transmission to humans occurs through intermediate hosts like pigs (NiV) and horses (HeV) ([@bib107]). Ephrin B2, which has been identified as the cellular receptor of henipaviruses, is highly conserved and present on endothelial cells, smooth muscle cells, and neurons ([@bib55]), and thus thought to contribute to the broad species and tissue tropism ([@bib15]). In humans, the Henipavirus case fatality rate is approximately 70%. The disease starts with influenza-like symptoms such as fever, dry cough, sore throat, and lymphadenopathy, often leading to acute respiratory distress symptom (ARDS) ([@bib73]). There is a high incidence of neurologic symptoms and survivors often experience neurologic sequelae months and even years after the acute infection ([@bib133], [@bib148], [@bib184], [@bib208]).

Ferrets experimentally infected with NiV or HeV develop the full spectrum of disease seen in humans. First clinical signs occur 6--10 days after infection, starting with fever, coughing, nasal discharge, shortness of breath, and depression, sometimes followed by limb paralysis and meningitis ([@bib17], [@bib137], [@bib138]). Comparison of NiV strains isolated from patients in Bangladesh and Malaysia revealed differences in the amount of virus shed in oral secretions of infected ferrets, which may explain the increased human-to-human transmissions seen during outbreaks in Bangladesh ([@bib31]). However, more extensive pathogenesis and transmission studies are limited by the high containment requirements for the work with these viruses. A recently generated recombinant HeV expressing GFP or luciferase from an additional open reading frame retained the ability to cause fatal disease in ferrets, thus constituting a valuable tool to directly characterize dissemination and to visualize virus--host interactions ([@bib115]).

While there is currently no vaccine or antiviral treatment approved for humans, a HeV vaccine for horses based on soluble HeV glycoprotein has been available since 2012. Efficacy studies in ferrets were instrumental in the development of this vaccine ([@bib16], [@bib122], [@bib138]), and the analogous approach against NiV protected ferrets from NiV challenge for more than 12 months ([@bib24], [@bib139]). A vesicular stomatitis virus pseudotyped with the NiV glycoproteins was equally protective in ferrets, indicating that the development of an efficient and safe vaccine against these viruses is feasible ([@bib123]). In addition, the potential of monoclonal antibody treatment has also been demonstrated in ferrets using a monoclonal antibody, which blocks the receptor-binding domain of the HeV and NiV G glycoproteins ([@bib17]), further validating ferrets as animal model for these viruses.

Pneumoviruses {#s0025}
-------------

Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) belong to the *Pneumovirinae* subfamily in the *Paramyxoviridae* family. They are one of the leading causes of respiratory disease in children worldwide, each year affecting more than 33 million children under the age of five as well as elderly and individuals with pre-existing respiratory conditions ([@bib48], [@bib128], [@bib198]). These viruses are transmitted via respiratory droplets or through direct contact with respiratory secretions ([@bib64]). The infection is limited to respiratory epithelial cells ([@bib106]), and the disease is mostly characterized by coughing, sneezing and fever. However, newborns, especially prematurely born infants, can progress to apnea, feeding difficulties, and periodic breathing ([@bib36], [@bib37], [@bib199]). In elderly patients, the infection often leads to pneumonia and chronic pulmonary disease, asthma, and congestive heart failure ([@bib47], [@bib48]). There is currently no vaccine against hRSV or hMPV, and the only approved antiviral drugs are ribavirin and a humanized monoclonal antibody directed against the RSV F glycoprotein ([@bib82]).

Ferrets are susceptible to hRSV and hMPV infection, and the viruses replicates to high titers in the nasal tissues ([@bib34]). However, hMPV-infected ferrets show no signs of disease ([@bib109]). When animals were infected early in life, hRSV causes acute and chronic changes in the neural control of the airways that persist long after the virus was cleared ([@bib35], [@bib96]). Ferrets were also used to investigate the potential of recombinant adenoviruses expressing the RSV fusion and attachment glycoproteins individually or in combination. After intranasal administration, strong RSV-specific antibody responses were observed, and the animals were protected from subsequent RSV challenge ([@bib74]). Since replication in the lung only takes place in infant ferrets ([@bib150]), their use as animal model for pneumovirus pathogenesis studies has been limited and little is known about the cellular receptors or mechanisms involved, even though ferrets reproduce the age-dependent differences in disease severity seen in humans.

Morbilliviruses {#s0030}
---------------

Ferrets are not susceptible to measles virus (MeV), the member of the Morbillivirus genus infecting humans and certain non-human primates. However, they are very sensitive to canine distemper virus (CDV), which infects a broad range of terrestrial and aquatic carnivores, and the disease reproduces all key elements seen in MeV-infected patients ([@bib108]). Because of the high degree of genetic, structural, and functional conservation among morbilliviruses and the consistent course of disease caused by CDV in ferrets, this model is frequently used to characterize common morbillivirus pathogenesis mechanisms. Upon infection with a CDV wild type strain via the respiratory route, virus can first be isolated from peripheral blood mononuclear cells (PBMC) after 2--3 days, and most T and B lymphocytes in lymphatic organs are CDV-positive within one week ([@bib147]). This coincides with a dramatic drop in white blood cell numbers and the loss of PBMC proliferation activity upon non-specific stimulation ([@bib203]). While the decrease in white blood cells is seen in all infections, the extent of inhibition of PBMC proliferation activity and of innate immune activation correlates with disease severity ([@bib182]). The latter is controlled by the accessory V protein ([@bib153], [@bib161]), and a recent study in ferrets revealed that inhibition of STAT2 and mda5 signaling is essential for morbillivirus-mediated interference with the innate immune response ([@bib180]). After the signaling lymphocyte activation molecule (SLAM) was identified as morbillivirus immune cell receptor ([@bib186], [@bib187]), pathogenesis studies with SLAM-blind viruses, first with CDV in ferrets and then with MeV in macaques, revealed that immune cell infection is essential for immunosuppression and clinical disease, thereby confirming the "immune cells first" hypothesis ([@bib97], [@bib202]).

After amplification in lymphatic organs, the virus spreads to epithelial tissues throughout the body. If the immune response is not sufficient to control and subsequently clear the virus, the loss of epithelial integrity eventually leads to septicemia and death within three to five weeks after infection. The recently identified epithelial cell receptor nectin-4 ([@bib125], [@bib132]) has enabled the generation of nectin-4-blind viruses, which subsequently not only illustrated the importance of epithelial cell infection for clinical disease but also demonstrated that acute immunosuppression requires immune but not epithelial cell infection ([@bib53], [@bib167]). Since the incidence of neuroinvasion in ferrets can reach 100% for some strains, they have also been used to investigate morbillivirus neuropathogenesis mechanisms. In addition to the previously known entry routes via the choroid plexus and small blood vessels, the anterograde infection along the olfactory nerves was identified as an additional entry pathway ([@bib164]). Comparative studies with different strains revealed a correlation with longer disease duration and less severe immunosuppression ([@bib14]).

The study of CDV in ferrets as a surrogate for MeV in primates has also been used to investigate the potential of novel vaccines and, more recently, an antiviral drug candidate ([@bib91], [@bib162], [@bib207]). The consistent pathogenesis together with the availability of robust reverse genetics systems for several vaccine and wild type strains thus make the CDV-ferret model an attractive system to characterize virus-host interactions in the context of lethal disease outcome or survival, and to investigate the impact of interventions at different stages of disease.

Coronaviruses {#s0035}
=============

In addition to viruses causing a mild upper respiratory tract infection, the *Coronavirinae* subfamily also includes members that lead to severe acute respiratory disease with mortality rates of around 10% for severe acute respiratory syndrome (SARS)-CoV and even higher for Middle East respiratory syndrome (MERS)-CoV ([@bib26], [@bib77]). Because of the respiratory tropism, the susceptibility of ferrets was evaluated. In the case of SARS-CoV, the virus was found to replicated efficiently in the upper and lower respiratory tract, and the animals developed clinical disease characterized by nasal discharge, sneezing, fever, and virus shedding including contact transmission to naïve cage mates after intratracheal infection ([@bib30], [@bib116]). However, no clinical signs were seen after intranasal infection in a different study ([@bib206]). This variability may be due to the route of infection, and the age, gender, and genetics of the animals are likely additional contributing factors.

In humans, the SARS-CoV tropism reflects the distribution of the cellular receptor angiotensin-converting enzyme (ACE) 2 ([@bib42], [@bib100]) in lung alveolar epithelial cells, enterocytes of the small intestine and tubular cells of the kidney ([@bib41], [@bib61], [@bib66]). The disease can range from mild respiratory signs to severe respiratory failure. After incubation period of 2--14 days patients initially present with influenza-like symptoms, fever, and cough that can progress to atypic pneumonia and respiratory failure ([@bib142]). The virus can also spread to multiple organs including the gastrointestinal and urinary tract causing a systemic disease. Even though it has been shown that ferret ACE2 interacts efficiently the SARS-CoV receptor-binding spike (S) protein ([@bib216]), the tropism of SARS-CoV in ferrets does not match the receptor distribution ([@bib60]), which may explain the differences in clinical manifestation observed.

Nevertheless, the ferret represents a useful animal model for the safety and efficacy assessment of SARS-CoV vaccine candidates and therapeutic approaches. While a MVA-based vaccine expressing the SARS-CoV S protein elicited a strong neutralizing immune response and protected the animals from disease, inflammatory lesions were found in the liver of the vaccinated animals ([@bib206]). Formalin-inactivated whole-virus vaccines as well as an S-expressing adenovirus-based vaccine also induced neutralizing antibodies and no liver pathology was noted, but the extent of protection varied, indicating that that a combination of vaccine strategies may be required for effective protection ([@bib38], [@bib168]). Prophylactic treatment with a monoclonal antibody reduced the replication of SARS-CoV in the lungs of infected ferrets up to one thousand-fold and may thus be useful in protecting contacts thereby limiting the spread of the disease ([@bib189]).

In the case of MERS-CoV, which also causes a severe pulmonary disease in humans, similar to SARS-CoV ([@bib215]), ferrets were not found to be susceptible. Even though MERS-CoV and SARS-CoV are both members of the genus *Betacoronavirus*, they differ in their receptor usage. MERS-CoV uses dipeptidyl peptidase (DPP) 4 for cell entry ([@bib152]), which can also be found on ferret cells, but the sequence differences between the human and ferret DPP4 protein prevent binding of MERS-CoV ([@bib200]) explaining the lack of infection in this species.

Others {#s0040}
======

Even though rabies pathogenesis is mostly studied in dogs, raccoons, or foxes, the protective efficacy of a commercial, inactivated rabies vaccine has also been demonstrated in ferrets ([@bib165]). In the context of a pathogenesis study, experimentally infected ferrets were assessed for susceptibility, incubation period, morbidity, clinical signs, seroconversion, and virus shedding. Interestingly, 17 out of 55 ferrets survived the infection, and rabies virus was isolated only from one of these animals ([@bib131]). Survival of ferrets experimentally infected with rabies virus was also reported in a different study ([@bib65]), indicating that they might be more resistant than other carnivores. Ferrets were also used to characterize newly discovered lyssaviruses with zoonotic potential and to evaluate the efficacy and cross-protection of available rabies vaccines ([@bib67], [@bib204]).

The potential of ferrets as an animal model has been evaluated for other viral diseases, including mumps virus, simian virus 5, canine or human parainfluenza viruses, and rubella virus. Two recent studies demonstrated that mumps virus-infected ferrets mounted robust humoral and cellular immune response but developed no clinical signs and no virus was shed, indicating that the use of the model is limited ([@bib140], [@bib210]). Ferrets infected with simian virus 5 or canine and human parainfluenza viruses, which generally cause a mild and transient disease in their natural hosts, develop antibody responses and histopathological changes indicative of an infection in the upper respiratory tract similar to those seen in other species, and may thus be an attractive model for the development of vaccines or antivirals ([@bib28], [@bib44], [@bib117], [@bib118]). Finally, during the late sixties, the use of ferrets as an animal model for neonatal rubella was explored but this was ultimately unsuccessful ([@bib45], [@bib46], [@bib159]).

Conclusion {#s0045}
==========

Ferrets have been used as animal models in viral research since the beginning of the 20th century, starting with influenza and, as their susceptibility for human respiratory viruses became increasingly apparent, followed by an ever increasing number of additional pathogens ( [Table 1](#t0005){ref-type="table"}). Even though their housing requirements are more elaborate than those for rodents, ferrets can still be accommodated in most animal facilities, and animals can be purchased from several commercial sources. The greatest disadvantage of the ferret as an animal model remains the relative lack of species-specific reagents. Although international efforts have been made to improve this situation by generating ferret-specific tools and by identifying cross-reactive reagents ([@bib50], [@bib166]), ferret immune responses are still poorly characterized. In addition, the potential of the model to characterize the contribution of opportunistic infections and different routes of inoculation, the dynamics of aerosol transmission, and infections in the context of immunosuppression or co-morbidities is just beginning to be explored ([@bib3], [@bib62], [@bib76], [@bib87], [@bib120], [@bib143]). Because of its great public health relevance, most of the studies to date have focused on influenza viruses, but an extension to other pathogens is likely to follow in the near future.Table 1Research topics studied in ferrets.**VirusesTransmissionPathogenesisNeurovirulenceImmune responseVaccination strategiesAntivirals and treatmentOrthomyxoviruses**Influenza A viruses**++++++ParamyxovirusesMorbilliviruses**Canine distemper virus (CDV)**++++++**Measles virus (MeV)**ØØØØØØHenipaviruses**Nipah virus (NiV)**−++−++**Hendra virus (HeV)**−+−−++Rubulaviruses**Mumps virus (MuV)**−+−+−−**Human parainfluenza virus (hPIV) 2**−+−+−−**Simian virus (SV) 5**−−−+−−Respiroviruses**Human parainfluenza virus (hPIV) 1, 3**−+−+−−Pneumoviruses**Human metapneumovirus (hMPV)**−+−−−−**Human respiratory syncytial virus (hRSV)**−++−+−RhabdovirusesLyssaviruses**Rabies virus**−++−+−TogavirusesRubiviruses**Rubella virus**+** (vertical)**−−−−−CoronaviridaeBetacoronaviruses**SARS-Coronavirus (SARS-CoV)**++−++−**MERS-Coronavirus (MERS-CoV)**ØØØØØØ**[^1][^2][^3]

The completion of the ferret genome and the publication of the ferret transcriptome ([@bib25], [@bib144]) also open new avenues of experimentation. Not only is it possible to identify transcribed mRNA or activated genes at a given time point of any viral infection, but the ferret genome information also facilitates the development of species-specific genomic and proteomic tools and the mapping of signaling pathways. After succeeding with somatic cell nuclear transfer ([@bib101]), the CFTR-knockout ferret as a cystic fibrosis model ([@bib178]) provided proof-of-concept for the generation of transgenic animals with specific phenotypes, and technical advances in the transgenics field such as the use of sleeping beauty transposons ([@bib79]) and the CRISPR-Cas system ([@bib63], [@bib185]), will put transgenic ferrets within the reach of the infectious disease research community. As new viruses continue to emerge and additional immunologic, genomic, and proteomic tools for ferrets become available, the importance of this animal model for infectious disease research will likely continue to increase.

[^1]: **+**: published.

[^2]: **−**: not published.

[^3]: **Ø**: no infection.
